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Pnkd immunochemistry in mouse brain. (A) Oligopeptides used to produce PNKD antibodies. Black rectangles represent exons shared by 
PNKD-L and PNKD-S; white rectangles represent exons shared by PNKD-L and PNKD-M; red rectangle represents the unique exon 1 of 
PNKD-M; blue rectangle represents the unique exon 3 of PNKD-S. Cysteines (underlined) were introduced in both oligopeptides to improve the 
coupling process. (B) Whole brain extracts on Western blots. The C-terminal antibody (1:5000 dilution) detected bands representing Pnkd-L 
(~47 kDa) and Pnkd-M (~40 kDa). The N-terminal antibody (1:500 dilution) detected bands representing Pnkd-L and Pnkd-S (~18 kDa). Pre-I, 
blots incubated with preimmune sera; Ag/Ab, PNKD antisera incubated with the oligopeptide against which they were raised; Ab, C- or N-terminal 
antisera only. (C) Double labeling in mice striatum with PNKD antibodies and either DARPP-32 (medium spiny neurons), ChAT (for cholinergic 
interneurons), or parvalbumin (Parv) (for GABAergic interneurons). (D) In striatum, Pnkd colocalizes with NeuN, a neuron-specific marker. (E) In 
striatum, Pnkd did not colocalize with oligodendrocyte-specific marker MBP. (F) Spinal cord cross section. Pnkd did not colocalize with astrocyte-
specific marker GFAP. Original magnification, ×400.
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Pnkd mice have lower striatal dopamine release at rest, but an 
increased percentage of striatal dopamine release in response to chal-
lenges. To examine the pattern of nigrostriatal dopamine release, 
we performed in vivo microdialysis in alert, freely moving mice. 










PNKD-L is a membrane-associated 
protein. (A) Immunostaining studies of 
permeabilized and nonpermeabilized 
HEK293 cells indicate that PNKD-L is a 
membrane-associated protein. HEK293 
cells are transfected with PNKD-EGFP 
followed by immunohistochemical 
staining using N- and C-terminal PNKD 
antibodies and Cy3-conjugated goat 
anti-rabbit IgG secondary antibody. 
Both PNKD N- and C-terminal antibod-
ies detect transfected PNKD-L–EGFP 
in permeabilized HEK cells, but fail to 
detect it in nonpermeabilized HEK cells. 
Scale bars: 10 microns. (B) Detergent 
phase partitioning of HEK293 mem-
brane fraction transfected with PNKD-
L–EGFP. The PNKD-L–EGFP (~75 
kDa) can be detected in crude mem-
brane fraction by both PNKD antibod-
ies, but after TX-114 treatment, the 
PNKD-L–EGFP can be detected in the 
hydrophilic layer, but not in the hydro-
phobic layer.
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Generation of Pnkd-transgenic and -KO mice. (A) 2 human mutations (A7V and A9V) were introduced into the BAC containing Pnkd. 62 kb 
of flanking sequence 5′ of the ATG start site is present in the BAC and is expected to contain all of the cis-acting regulatory elements leading 
to expression in a pattern faithful to the endogenous alleles. An internal ribosome entry site (IRES) followed by an enhanced red fluorescent 
protein gene (IRES/DsRed) was introduced into the 3′ UTR of the Pnkd gene. The original BAC without mutations was used for generation of 
Pnkd WT-Tg mice. (B) Southern blot analyses of mutant and WT-Tg mice. (C) Western blot analyses of brain extracts from mut-Tg and WT-Tg 
mice with C-terminal antibody. Tubulin was used as loading control. (D) Pnkd-KO mice. A short homologous arm upstream of exon 5 and a long 
homologous arm downstream of exon 9 were amplified and subcloned into the pMCIDT-A PGKNeo vector to replace 1.5 kb of genomic Pnkd 
DNA (including exons 5–9) with a neomycin resistance gene. (E) Genotype analyses of Pnkd-KO mice by RT-PCR. (F) Western blot analyses 
of mut-Tg and KO mice using C-terminal antibody. Tubulin was used as loading control. *Pnkd-L (~47 kDa); **Pnkd-M (~40 kDa).
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Pnkd mutant mice (mut-Tg, Pnkd mice) recapitulate the PNKD phenotype and have altered dopamine signaling. (A) Quantifying activity of Pnkd 
mice and WT littermates after caffeine injection (25 mg/kg, i.p.). Caffeine-induced hyperkinetic movements in mutant mice. (B) Activity ratings of 
Pnkd mice and WT littermates after saline injection (10 ml/kg, i.p.). A slight increase in activity was observed in Pnkd mice 30–50 minutes after 
saline injection. (C) The mut-Tg mice manifested profound dyskinesia after injection of ethanol (1.5 g/kg, 20% v/v, i.p.), but the same treatment 
failed to induce hyperkinetic movements in WT littermates. Activity ratings are expressed as mean ± SEM (n = 8 for each group). (D) There were 
no obvious differences in the dopamine levels in striatal extracts from mice of various genotypes at rest or after caffeine treatment. (E and F) 
Both DOPAC levels and DOPAC/dopamine ratios were significantly increased in Pnkd mice (P < 0.01) after caffeine treatment, but decreased 
in WT and KO mice (P < 0.01). (G) The HVA levels at rest versus after caffeine treatment were significantly increased in Pnkd mice (P < 0.05). 
All data are presented as mean ± SEM. *P < 0.05; **P < 0.01.
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In vivo microdialysis of Pnkd mice. (A) Striatal dopamine concentrations were measured by no net flux microdialysis (mut-Tg, n = 7; WT, n = 5). 
Decreased levels of extracellular dopamine were observed in striata of Pnkd mice (P < 0.005). ** P < 0.01. (B) No significant difference in extrac-
tion fractions was found between genotypes. (C) Dopamine concentrations at basal levels and after stress/caffeine stimulation were reduced in 
striata of Pnkd mice (P < 0.005, n = 7) versus controls (n = 5). (D) Higher levels of dopamine release in response to stress and caffeine injection 
were observed in striata of Pnkd versus WT mice (P < 0.05). All data are shown as mean ± SEM.
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Amperometry studies of Pnkd mice. (A) The 
amperometry traces of Pnkd mice versus WT 
littermates. (B) The mean evoked dopamine 
signal amplitude was significantly decreased in 
striatal slices from Pnkd mice versus controls 
with or without nomifensine (P < 0.01). (C) Stri-
atal slices from Pnkd mice showed significantly 
reduced dopamine release per stimulation 
(P < 0.05). Application of nomifensine restored 
the overall stimulated dopamine release. (D 
and E) Striatal slices of Pnkd mice showed 
significant reduction of the spike width and 
elevated half width (t1/2) of dopamine release 
(P < 0.05). Only the spike width of Pnkd slices 
was restored in the presence of nomifensine. 
In contrast, application of nomifensine did not 
restore the half width of Pnkd mouse striatal 
slices (P < 0.01). All data are presented as 
mean ± SEM. * P < 0.05; ** P < 0.01.
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Pharmacological studies of Pnkd mice. (A) There are significant hyperkinetic movements in Pnkd (mut-Tg) mice (versus littermate controls) 
after injection of the adenosine A2 receptor antagonist CSC (5 mg/kg, i.p.). (B) No difference in activity ratings of Pnkd mice and WT littermates 
was observed after injection of the adenosine A1 receptor antagonist DPCPX (3 mg/kg, i.p.). (C) There are significant hyperkinetic movements 
in Pnkd mice after injection of the dopamine D2 receptor agonist quinpirole (2.5 mg/kg, i.p.). (D) Increased activity was observed in both Pnkd 
mice and WT controls after injection of SKF 82958 (D1 receptor agonist, 0.75 mg/kg, i.p.), but no difference was found between genotypes. In 
all pharmacological studies, behavioral ratings are expressed as mean ± SEM (n = 8 for each group).
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Supplemental Figure 1 
Western blot analyses of HEK293 cell extractions transfected with different isoforms 
of PNKD-EGFP by using PNKD antibodies and GFP antibody. PNKD N-terminal 
antibody can detect both PNKD-L-EGFP (~75 kDa) and PNKD-S-EGFP (~44 kDa), 
and PNKD C-terminal antibody can detect both PNKD-L-EGFP and PNKD-M-EGFP 
(~70 kDa). GFP antibody can positively identify all three EGFP-fusion proteins at 
similar sizes compared with PNKD antibodies.    
 





Supplemental Figure 2 
Pnkd immunochemistry in mouse brain. (A) Pnkd is expressed in substantia nigra pars 
reticulata (SNR), and substantia nigra pars compacta (SNC). In SNC, Pnkd is 
co-localized with the dopaminergic neurons which are positive for tyrosine 
hydroxylase (TH). Original magnification, x400. (B) In cerebellum, Pnkd is widely 
expressed in the Purkinje cells, and the molecular and granule cell layers. Purkinje 
cells and neurons in the molecular layer are co-labeled with anti-glutamate 




Supplemental Figure 3 
 
 
Supplemental Figure 3  
After caffeine treatment, strong c-Fos staining is detected in the basal ganglia of Pnkd 
(mut-Tg) mice vs. WT littermates but no obvious differences in 5-HT signaling 
pathways of PNKD mice or WT littermates were seen. (A) c-Fos 
immunohistochemistry in basal ganglia of Pnkd mice and WT littermates 2 hours after 
caffeine stimulation. Strong induction of c-Fos was detected in the lateral globus 
pallidus, subthalamic nucleus, and substantia nigra pars reticulata of Pnkd mice, but 
not in WT littermates. Abbreviations: Cpu, caudate putamen; LGP, lateral globus 
pallidus; STh, subthalamic nucleus; SNR, substantia nigra pars reticulata. Original 
magnification, x50. (B, C) There were no changes in the levels of serotonin (5-HT) or 
5-hydroxyindoleacetic acid after caffeine treatment. All data are presented as mean ± 














Supplemental Figure 4  
Western analysis shows no differences between Pnkd (mut-Tg) mice and WT 
littermates for a number of dopamine signaling and metabolism proteins, but the 
dopamine receptor, dopamine transporter, and monoamine oxidase B proteins are 
up-regulated in Pnkd mice. (A) No difference was found between genotypes for the 
expression levels of tyrosine hydroxylase (TH) in striatum of Pnkd mice and WT 
controls. (B) The protein levels of dopamine D1A receptor (D1AR) is significantly 
higher in Pnkd mice compared with WT littermates (P<0.05). (C) The protein levels 
of dopamine D2 receptor (D2R) is up-regulated in Pnkd mice compared with WT 
littermates (P<0.05) (D) The protein levels of vesicular monoamine transporter 2 
(VMAT2) trended to being decreased in Pnkd mice vs. controls but the difference was 
not statistically significant. (E) The protein levels of dopamine transporter (DAT) is 
significantly higher in Pnkd mice compared with WT littermates (P<0.05). (F, G, H) 
There were no obvious differences in expression levels of two isoforms of catechol 
o-methyltransferase (COMT) and monoamine oxidase A (MAO-A) between 
genotypes, but the amount of monoamine oxidase B (MAO-B) is significantly 


























Supplemental Figure 5  
Western analysis shows no differences between Pnkd (mut-Tg) mice and WT 
littermates for a number of striatal proteins. There were no differences in expression 
levels of (A) Rab3a, (B) synapsin-1, and (C) synaptophysin, (D, E) glutamate 
decarboxylase 65 and 67 (GAD65 and GAD67), (F) There were no differences in 
expression levels of excitatory amino acid transporter 3 (EAAT3), (G) vesicular 
glutamate transporter (VGLUT1), (H, I) adenosine A1 and receptors (A1R, A2AR), and 
(J) adenosine kinase (ADK) in mutant vs. control animals. All data are given as mean 
± SEM (n = 8 for each genotype). 





Supplemental Figure 6 
A1A and A2 Receptor Neuropharmacology. (A) No difference in activity ratings of 
Pnkd mice (mut-Tg) and WT littermates (WT) were observed after adenosine A1 
receptor agonist CPA (0.1 mg/kg, IP) or (B) adenosine A2 receptor agonist CGS21680 
(0.5 mg/kg, IP). Reduced activity was observed after treatment with CGS 21680, but 
no obvious difference is found between genotypes. These behavioral ratings are 




Figure legends of supplemental videos 
 
Supplemental video 1. 
Stress induced dyskinetic attacks in Pnkd mouse. In Pnkd (mut-Tg) mouse, stress by 
prolonged handling (>15-30 minutes) induced dyskinetic attacks. 
 
Supplemental video 2.  
Caffeine induced dyskinetic attacks in Pnkd mouse. In Pnkd (mut-Tg) mouse, caffeine 
(25 mg/kg) induced dyskinetic attacks ~15-20 minutes after treatment. 
 
Supplemental video 3.  
Ethanol induced dyskinetic attacks in Pnkd mouse. Ethanol (1.5 g/kg, 20% v/v) also 
induced dyskinetic attacks in the Pnkd (mut-Tg) mouse (right side) but not in WT 




PNKD Antibodies.  Polyclonal antibodies were developed (Covance, Berkeley, CA) 
using two synthesized oligopeptides corresponding to the N-terminus of PNKD-L and 
S (MAAVVAATALKGRGARNARVLRGC), and the C-terminus of PNKD-L and M 
(CDDYSRAQLLEELRRLKDMHKSK). Pre-immune bleeds and test bleeds were 
obtained individually from the supplier to monitor antibody titer and specificity in 
subsequent bleeds. Antibodies were affinity-purified using the oligopeptides coupled 
to activated CH-Sepharose 4B beads (Amersham Biosciences, Piscataway, NJ). 
Antisera were added to the bead preparations, rotated, and incubated overnight at 4°C. 
Antiserum/bead mixtures were then poured into a 10 mL Poly-prep chromatography 
column (Bio-Rad, Hercules, CA), washed with four bead volumes of 1X 
phosphate-buffered saline (PBS) without calcium and magnesium (Gibco, Carlbad, 
CA), and eluted with 40 X 500μL fractions of 100mM glycine (pH 2.7) into 
microcentrifuge tubes containing 300μL 200mM Na2HPO4. Absorbance at 280nm was 
determined using the Coomassie PlusProteinAssay kit (Pierce Biotechnology, 
Rockford, IL) for each fraction with a DU 530 UV/Vis spectrophotometer (Beckman 
Coulter, Fullerton, CA). Affinity-purified antibodies were then used for Western 
blotting and immunohistochemistry experiments. 
Generation of Pnkd transgenic mice.  RP24-112K19 is a bacterial artificial 
chromosome (BAC) clone from the RP-24 mouse genomic library containing the 
entire Pnkd locus on a 183-kb genomic insert with 62kb upstream of the gene 
(Children’s Hospital Oakland Research Institute). We constructed a rpsl/kan counter 
selection fragment. The primers were designed with 20 nucleotides for amplification 
of the rpsl/kan gene and an additional 50 nucleotides homologous to sequences 
flanking the region corresponding to the mutant region. This PCR product was 
transferred into the RP24-112K19 BAC by homologous recombination in E. coli 
strain DH10B already containing the plasmid pKD46 (1). The counter selection gene 
was removed by recombination using a synthetic oligonucleotide in the position 
carrying the Ala7Val and Ala9Val mutations as described elsewhere with modification 
(2). ET-cloning was then employed to introduce an internal ribosome entry site (IRES) 
followed by an enhanced red fluorescent protein gene (IRES/DsRed) into the 3’ UTR 
of the Pnkd gene. All relevant segments generated by PCR and recombination were 
sequence confirmed. Purified BAC DNA (Nucleobond, BD) was subjected to 
Southern blotting to confirm correct homologous recombination. BAC DNA was 
digested with NotI restriction enzyme, run on a pulse field gel to identify the best 
samples to inject, and concentration of BAC DNA without linearization for injection 
was adjusted to 1 ng/µL with microinjection buffer. WT transgenic mice were 
generated by microinjecting an unmodified BAC clone. The transgenic founders had a 
mixed C57BL/6XSJL F1 background and were backcrossed to C57/BL6 for >10 
generations. 
Generation of Pnkd knockout mice. To generate the targeting vector, a 2.6 kb short 
homologous arm upstream of Pnkd exon 5, was amplified with the LA PCR kit 
(Takara, Japan) using primers 5’- 
GCCCGGGCAGAAAGAGAGCGAAGTCAGAGAAG-3’ and 5’- 
CTCGAGGAGCTCAGTACTGTCTGTAGGCCTCACATCTCTAGG-3’. A 6.5 kb 
long homologous arm, which is down stream of exon 9 was amplified using primers 
5’ CTCGAGGTGGTGAGTTTCTGCAAAAGAGAG-3’ and 5’- 
ATCAGGTTTCCATGGTTTTGCTAT-3’. The fragments were inserted separately into 
the pMCIDT-A PGKNeo vector. About 1.5kb of genomic DNA, including exons 5 to 
9, was replaced by the neomycin resistance gene. The targeting vector was linearized 
with NotI and used for electroporation into embryonic stem (ES) R1 cells. Culture of 
ES cells and isolation of homologous recombinants were performed according to 
standard protocols. Briefly, 107 R1 ES cells were transfected with 25 to 50 µg of the 
linearized vector. Cells were cultured under selection in G418. Resistant colonies were 
expanded in 96-well plates. Screening for homologous recombinants by PCR used 
amplification of external short arm area primer 5’- 
AGAGGCCACAGAAGGGAAGT-3’ and vector side 
5’GCCTCACATCTCTAGGATCTCTGT-3’, and vector side 5’- 
GTTCTTCTGAGGGGATCAATTCTCTA-3’ and external long arm area 5’- 
GATCCTTATAGGTCAAAGAGCAGGAG-3’. Positive ES clones were injected into 
C57BL/6J blastocysts and implanted in pseudopregnant females. Chimeric mice were 
screened using PCR and Southern blotting to detect recombinants and mated with 
C57BL/6 mice to produce F1 heterozygous mice and heterozygotes identified by PCR. 
Confirmed Pnkd +/- F1 mice were backcrossed to C57BL/6J mice or mated with 
siblings to generate null mutant mice. 
Genotyping. PCR was performed on genomic DNA isolated from tail cuts of Pnkd 
transgenic, KO, and WT mice. PCR was performed using the following primer sets: 
5’-TAGCGCTACCGGACTCAGAT-3’ and 5’-AGGAACTGCTTCCTTCACGA-3’ 
(mutant transgenic), 5’-AGTGCAGTCGTAAAAGTCAGAAC-3’ and 
5’-ACATACATGCAGGAAAACAACCA-3’ (WT transgenic), and 
5’-AGGATCTCCTGTCATCTCACCTTGCTCCTG-3’ and 
5’-AAGAACTCGTCAAGAAGGCGATAGAAGGCG-3’ (KO mice). PCR was for 3 
minutes at 94°C, 35 cycles of amplification (30s at 94°C, 30s at 60°C, and 60s at 
72°C), followed by 3 minutes final extension at 72°C. 
Immunoblotting. For Western blotting tissue homogenates obtained from Pnkd WT, 
transgenic and KO mice, protein concentrations were determined using a protein 
assay kit (Pierce, Rockhold, IL). Brain homogenates containing 20μg of protein were 
resolved on 10% polyacrylamide gels and electroblotted to nitrocellulose membrane 
using 50mM Tris-HCl buffer (pH 8.4). The blot was incubated with anti-PNKD 
antibody for 1 hour and detected using an ECL western blot chemiluminescent kit 
(GE Healthcare, Buckinghamshire, UK). Blots were stripped and reprobed with an 
anti-α-tubulin antibody (1:5000; Sigma, St. Louis, MO). Densitometry was performed 
using a Kodak 1-D system (Eastman Kodak, Rochester, NY). Pnkd levels were 
normalized to α-tubulin using the average pixel intensity for immunoreactive band in 
each lane and the images were analyzed by the NIH ImageJ software. 
 For the comparison of the levels of different proteins in striata of Pnkd mice and 
WT littermates, the dorsal striata of mice (n=8/genotype) were dissected and snap 
frozen in liquid nitrogen. Striata were sonicated in 300 μl of RIPA buffer (10mM 
Tris-HCl pH 7.2, 150mM NaCl, 5mM EDTA, 1% Triton X-100, 1% SDS, 1% 
Deoxycholate) with protease inhibitor (Roche, Mannheim, Germany) and phosphatase 
inhibitor cocktails (Sigma, St. Louis, MO). Equal amounts of protein from the total 
striatal homogenate were used for the Western blot analysis as described above. Blots 
were then incubated with one of the following antibodies in 1:1000 dilution: 
anti-vesicular glutamate transporter 1 (VGLUT1), anti-Rab3A and anti-synaptophysin 
(Synaptic Systems, Goettingen, Germany); anti-excitatory amino acid transporter 3 
(EAAT3), anti-monoamine oxidase A (MAO-A), and anti-monoamine oxidase B 
(MAO-B) (Santa Cruz biotechnology, Santa Cruz, CA); anti-adenosine kinase (ADK) 
(Abcam, Cambirdge, MA); anti-adenosine A1 receptor (A1R, EMD, Darmatadt, 
Germany); anti-catechol o-methyltransferase (COMT, BD biosciences, San Jose, CA); 
anti-synapsin-1, anti-glutamate decarboxylase 65 (GAD65), anti-glutamate 
decarboxylase 67 (GAD67), anti-adenosine A2A receptor (A2AR), anti-tyrosine 
hydroxylase (TH), anti-dopamine transporter (DAT), anti-dopamine D1A receptor 
(D1AR), anti-dopamine D2 receptor (D2R), and anti-vesicular monoamine transporter 2 
(VMAT2) (Millipore, Billerica, MA), Detected was performed as described above, 
and were stripped and reprobed with either anti-α-tubulin or anti-glyceraldehyde 
3-phosphate dehydrogenase (GAPDH) antibody (Millipore, Billerica, MA). Striata 
protein levels were normalized and data were analyzed using Student’s t test. 
RT-PCR. Total RNA was extracted from mouse brain with TRIzol (Invitrogen) 
according to the manufacturer’s instructions, and then subjected to DNase treatment 
(Ambion). RNA (10μg) was reverse-transcribed using Superscript III (Invitrogen). 
The primer sequence for Pnkd were 5’-TGCTATTCTTCGCCTTCGTGCTG-3’ and 
5’-CCTGGCCCCAGAGCCTCCTGTAGT-3’ (Pnkd-M), and 
5’-GGGGTGGGACCCGAACATGGCGGC-3’ and 
5’-CCTGGCCCCAGAGCCTCCTGTAGT-3’ (Pnkd-L). The following conditions 
were used for PCR: 3 minutes at 94°C, 35 cycles of amplification (30s at 94°C, 30s at 
55°C, and 60s at 72°C), followed by 3 minutes final extension at 72°C. 
Pnkd Immunohistochemistry in mice brain slides. Adult WT, and transgenic male 
mice were sacrificed, perfused, and brains/spinal cords were removed, fixed, 
postfixed, cryoprotected, and coronal sections were cut at 14 µm with a Leica 
CM1850 cryostat (Leica, Nussloch, Germany) and thaw-mounted onto Superfrost 
Plus slides (Fisher, Pittsburgh, PA). The sections were washed in 1 X PBST (PBS 
with 0.3% Triton X-100) for 5 minutes, then blocked by 10% normal goat 
serum-PBST (NGS-T) for 1 hour. Fluorescence immunohistochemistry staining was 
performed by incubating overnight in 2% NGS-T with PNKD N-terminal antibody 
(1:250 to 1:500 diluted) or PNKD C-terminal antibody (1:5000 diluted), and 
co-labeled with mouse monoclonal antibodies for detection of either neuron-specific 
nuclear protein (NeuN), glial fibrillary acidic protein (GFAP), myelin basic protein 
(MBP), dopamine- and cyclic AMP-regulated neuronal phosphoprotein with 
molecular weight 32 kDa (DARPP-32), choline acetyltransferase (ChAT), 
parvalbumin, glutamic acid decarboxylase isoform 67 (GAD67), or tyrosine 
hydroxylase (TH) (Chemicon, Temecula, CA). After three washes with 2% NGS-T, 
sections were then incubated in 2% NGS-T with CyTM3-conjugated goat-anti rabbit 
IgG (diluted 1:300), alone or combined with CyTM2-conjugated goat-anti mouse IgG 
(1:50) (Jackson ImmunoResearch, West Grove, PA) for 1 hour, followed by washing 
three times in 1 X PBS-T in darkness. The sections were mounted under cover slides 
with Vectashield mounting medium (Vector Laboratories Inc. Burlingame, CA). 
Images were captured with a Zeiss Pascal LSM5 confocal microscope in the UCSF 
microscopy core and were imported into Photoshop (Adobe Systems, San Jose, CA) 
for analysis. 
Immunostaining of transfected cells for PNKD-L localization. Human embryonic 
kidney (HEK)-293 cells were grown in Dulbecco’s modified Eagle’s medium 
(DMEM) supplemented with penicillin, streptomycin, and 10% fetal bovine serum 
(Hyclone, Logan, UT) and maintained at 37°C with 5% CO2. After one day, the cells 
were split into 35mm culture dishes on coverslips pre-coated with poly-L-lysine 
(Sigma, St. Louis, MO). In parallel, HEK293 cells grown to 80-90% confluence were 
transfected with 2 μg DNA (PNKD-L, M, and S WT fusion constructs) using 20 μl of 
Polyfect reagent (Qiagen, Valencia, CA) using a standard protocol. Twelve hours 
post-transfection, cells were quick fixed in 4% paraformaldehyde and permeabilized 
with PBS/0.1% Triton or incubated in PBS and then stained with either PNKD 
N-terminal or C-terminal antibody followed by CyTM3-conjugated goat-anti rabbit 
IgG (1:300) secondary antibody (Jackson ImmunoResearch, West Grove, PA) and 
mounted on Premium microscope slides (Fisher, Pittsburgh, PA) with Vectashield 
mounting medium (Vector, Burlingame, CA). Images were acquired using the Zeiss 
Pascal LSM5 confocal microscope in the UCSF microscopy core facility. 
Mapping of c-Fos induction after a precipitation of a PNKD attack. Two hours after 
intraperitoneal (IP) injection of ethanol or caffeine, mice were perfused intracardially 
under deep tribromoethyl alcohol anesthesia with PBS followed by 4% 
paraformaldehyde in PBS. Following perfusion, brains were post-fixed and sliced into 
30μM coronal sections using a vibratome. c-Fos immunohistochemistry was 
performed on free-floating brain slices. Brain sections were pretreated for 30 minutes 
0.5 hour with 0.5% solution of H2O2 and blocked with 4% inactivated normal goat 
serum for 30 minutes in PBS/0.3% Triton X-100 prior to being rinsed with normal 
PBS. The primary antibody (Ab2, Oncogene Research Products) was diluted 1:1000 
in PBS with 1% bovine serum alubumin (BSA)/0.3% Triton X-100 and incubated 
overnight at 4°C. Biotinylated goat anti-rabbit IgG (Oncogene Reseach Products) was 
diluted 1:400 in PBS with 1% BSA/0.3% Triton X-100. Sections were then incubated 
in avidin-biotin-horseradish peroxidase (Vectastain Elite ABC kit, Vector Laboratories 
Inc.) for 1 hour. Labeling was revealed by exposure to 3,3’-diaminobenzidine (DAB) 
substrate (Peroxidase Substrate kit, Vector Laboratories Inc.) for 10-15 minutes. The 
sections were then mounted under cover slides with Vectashield mounting medium 
(Vector Laboratories Inc. Burlingame, CA) and images were captured with a Nikon 
Eclipse microscope with a CCD camera or a Leica DM5000B microscope with a 
SPOT RT camera (SPOT diagnostic Inc., Sterling Heights, MI) and were imported 
into Photoshop program for analysis. 
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